drugset / Trial / NCT05350072
Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-1)
Timeline
- Start
- 2022-07-28
- Primary completion
- 2025-05-07
- Completion
- 2026-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ianalumab | Monoclonal antibody | — | Subcutaneous |